Share
.webp)
.webp)
.webp)
.webp)
Robert Plenge
BioMarin Pharmaceutical Inc. has appointed Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb (BMS), to its Board of Directors.
In his current role at BMS, Dr. Plenge leads the company’s scientific research activities across nine research sites worldwide, overseeing efforts focused on advancing innovative medicines. He joined BMS in November 2019 through the company’s acquisition of Celgene Corporation, where he served as Vice President of the Immunology and Inflammation portfolio within Research and Early Development.
Before joining Celgene, Dr. Plenge served as Vice President and Head of Translational Medicine at Merck & Co., where he was involved in advancing research and translating scientific discoveries into potential therapeutic applications. Earlier in his career, he was an Assistant Professor of Medicine at Harvard Medical School and an Associate Member of the Broad Institute.
In addition to his leadership roles in the pharmaceutical industry, Dr. Plenge serves on the boards of Alltrna and the PhRMA Foundation. His experience spans drug discovery, translational medicine, immunology and inflammation research, and scientific strategy.
Dr. Plenge earned both his M.D. and Ph.D. from Case Western Reserve University. He also holds a bachelor’s degree from the University of California, San Diego.
BioMarin said Dr. Plenge’s appointment brings extensive pharmaceutical research and development experience to its Board of Directors as the company continues to advance its portfolio of innovative therapies.
